{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:38:23Z","timestamp":1772037503033,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[1995,10,1]],"date-time":"1995-10-01T00:00:00Z","timestamp":812505600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[1995,10]]},"DOI":"10.1038\/nm1095-1082","type":"journal-article","created":{"date-parts":[[2004,8,19]],"date-time":"2004-08-19T01:02:21Z","timestamp":1092877341000},"page":"1082-1085","source":"Crossref","is-referenced-by-count":92,"title":["Genetic predisposition to adverse consequences of anti\u2013cholinesterases in \u2018atypical\u2019 BCHE carriers"],"prefix":"10.1038","volume":"1","author":[{"given":"Yael","family":"Loewenstein-Lichtenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Glick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bent","family":"N\u00f8rgaard-Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haim","family":"Zakut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermona","family":"Soreq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFnm10951082_CR1","doi-asserted-by":"crossref","unstructured":"Schwarz, M., Click, D., Loewenstein, Y. & Soreq, H. Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol Ther. (in the press).","DOI":"10.1016\/0163-7258(95)00019-D"},{"key":"BFnm10951082_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0009-9120(90)90187-Y","volume":"23","author":"BN La Du","year":"1990","unstructured":"La Du, B.N. et al. Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. Clin. Biochem. 23, 423\u2013431 (1990).","journal-title":"Clin. Biochem."},{"key":"BFnm10951082_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jama.1991.03470050093029","volume":"266","author":"JR Keeler","year":"1991","unstructured":"Keeler, J.R., Hurst, C.G. & Dunn, M.A. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA 266, 693\u2013695 (1991).","journal-title":"JAMA"},{"key":"BFnm10951082_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1001\/jama.1994.03510370075036","volume":"271","author":"MA Winker","year":"1994","unstructured":"Winker, M.A. Tacrine for Alzheimer's disease; which patient, what dose? JAMA 271, 1023\u20131024 (1994).","journal-title":"JAMA"},{"key":"BFnm10951082_CR5","first-page":"656","volume":"27","author":"Y Sharabi","year":"1991","unstructured":"Sharabi, Y. et al. Survey of symptoms following intake of pyridostigmine during the Persian Gulf War. Isr. J. med. Scl 27, 656\u2013658 (1991).","journal-title":"Isr. J. med. Scl"},{"key":"BFnm10951082_CR6","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/j.1460-2075.1992.tb05210.x","volume":"11","author":"LF Neville","year":"1992","unstructured":"Neville, L.F. et al Intramolecular relationships in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BCHE. EMBO J. 11, 1641\u20131649 (1992).","journal-title":"EMBO J."},{"key":"BFnm10951082_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1073\/pnas.86.3.953","volume":"86","author":"MC McGuire","year":"1989","unstructured":"McGuire, M.C. et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc. natn. Acad. Sci. U.S.A. 86, 953\u2013957 (1989).","journal-title":"Proc. natn. Acad. Sci. U.S.A."},{"key":"BFnm10951082_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0006-2952(59)90097-8","volume":"1","author":"W Kalow","year":"1958","unstructured":"Kalow, W. & Davis, R.O. The activity of various esterase inhibitors towards atypical human serum cholinesterase. Biochem. Pharmacol. 1, 183\u2013192 (1958).","journal-title":"Biochem. Pharmacol."},{"key":"BFnm10951082_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0163-7258(90)90044-3","volume":"47","author":"O Lockridge","year":"1990","unstructured":"Lockridge, O. Genetic variants of serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol. Ther. 47, 35\u201360 (1990).","journal-title":"Pharmacol. Ther."},{"key":"BFnm10951082_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1006\/geno.1994.1386","volume":"22","author":"G Ehrlich","year":"1994","unstructured":"Ehrlich, G. et al. Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes of Israeli Jews from Transcaucasian Georgia and from Europe. Genomics 22, 288\u2013295 (1994).","journal-title":"Genomics"},{"key":"BFnm10951082_CR11","volume-title":"Human Cholinesterases and Anticholinesterases","author":"H Soreq","year":"1993","unstructured":"Soreq, H. & Zakut, H. Human Cholinesterases and Anticholinesterases (Academic Press, San Diego, California, 1993)."},{"key":"BFnm10951082_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0169-328X(95)00040-Y","volume":"31","author":"M Schwarz","year":"1995","unstructured":"Schwarz, M. et al. Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants. Molec. Brain Res. 31, 101\u2013110 (1995).","journal-title":"Molec. Brain Res."},{"key":"BFnm10951082_CR13","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1128\/MCB.15.6.2993","volume":"15","author":"S Seidman","year":"1995","unstructured":"Seidman, S. et al. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 3\u2032-terminal exons. Molec. cell. Biol. 15, 2993\u20133002 (1995).","journal-title":"Molec. cell. Biol."},{"key":"BFnm10951082_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/bj2600625","volume":"260","author":"A Chatonnet","year":"1989","unstructured":"Chatonnet, A. & Lockridge, O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 260, 625\u2013634 (1989).","journal-title":"Biochem. J."},{"key":"BFnm10951082_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-1-4899-6738-1_29","volume-title":"Cholinergic Basis for Alzheimer Therapy","author":"E Giacobini","year":"1991","unstructured":"Giacobini, E. The second generation of cholinesterase inhibitors: Pharmacological aspects. in Cholinergic Basis for Alzheimer Therapy (eds Becker, R. & Giacobini, E.) 247\u2013262 (Birkhauser, Boston, 1991)."},{"key":"BFnm10951082_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0079-6123(08)62427-9","volume":"98","author":"LL Iversen","year":"1993","unstructured":"Iversen, L.L. Approaches to cholinergic therapy in Alzheimer's disease. Prog. Brain. Res. 98, 423\u2013426 (1993).","journal-title":"Prog. Brain. Res."},{"key":"BFnm10951082_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0079-6123(08)62429-2","volume":"98","author":"A Enz","year":"1993","unstructured":"Enz, A., Amstutz, R., Boddeke, H., Gmelin, G. & Malonowski, J. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease. Prog. Brain Res. 98, 431\u2013437 (1993).","journal-title":"Prog. Brain Res."},{"key":"BFnm10951082_CR18","doi-asserted-by":"publisher","first-page":"9031","DOI":"10.1073\/pnas.90.19.9031","volume":"90","author":"M Harel","year":"1993","unstructured":"Harel, M. et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. natn. Acad. Sci. U.S.A. 90, 9031\u20139035 (1993).","journal-title":"Proc. natn. Acad. Sci. U.S.A."},{"key":"BFnm10951082_CR19","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.1073\/pnas.89.22.10827","volume":"89","author":"M Harel","year":"1992","unstructured":"Harel, M. et al. Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis. Proc. natn. Acad. Sci. U.S.A. 89, 10827\u201310831 (1992).","journal-title":"Proc. natn. Acad. Sci. U.S.A."},{"key":"BFnm10951082_CR20","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/0006-2952(81)90392-0","volume":"30","author":"RJ Valentine","year":"1981","unstructured":"Valentine, R.J., Lockridge, O., Eckerson, H.W. & La Du, B.N. Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies. Biochem. Pharmacol. 30, 1643\u20131649 (1981).","journal-title":"Biochem. Pharmacol."},{"key":"BFnm10951082_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/369008a0","volume":"369","author":"H Gavageran","year":"1994","unstructured":"Gavageran, H. NIH panel rejects Persian Gulf syndrome. Nature 369, 8 (1994).","journal-title":"Nature"},{"key":"BFnm10951082_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0014-5793(82)80437-7","volume":"138","author":"P Ott","year":"1982","unstructured":"Ott, P., Lustig, A., Brodbeck, U. & Rosenbusch, J.P. Acetylcholinesterase from human erythrocyte membranes: Dimers as functional units. FEBS Lett. 138, 187\u2013189 (1982).","journal-title":"FEBS Lett."},{"key":"BFnm10951082_CR23","first-page":"22","volume":"149","author":"IM Johansson","year":"1993","unstructured":"Johansson, I.M. & Nordberg, A. Pharmacokinetic studies of cholinesterase inhibitors. Acta neurol. scand. Suppl. 149, 22\u201325 (1993).","journal-title":"Acta neurol. scand. Suppl."},{"key":"BFnm10951082_CR24","first-page":"412","volume":"41","author":"HA Berman","year":"1992","unstructured":"Berman, H.A. & Leonard, K. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase. Molec. Pharmacol. 41, 412\u2013418 (1992).","journal-title":"Molec. Pharmacol."},{"key":"BFnm10951082_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/j.1552-4604.1994.tb04001.x","volume":"34","author":"DG May","year":"1994","unstructured":"May, D.G. Genetic differences in drug disposition. J. clin. Pharmacol. 34, 881\u2013897 (1994).","journal-title":"J. clin. Pharmacol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm1095-1082","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1095-1082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1095-1082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:03:19Z","timestamp":1684447399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm1095-1082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1995,10]]}},"alternative-id":["BFnm10951082"],"URL":"https:\/\/doi.org\/10.1038\/nm1095-1082","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,10]]}}}